{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T08:06:25Z","timestamp":1773734785576,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Brain Res"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00221-018-5210-x","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T01:11:42Z","timestamp":1519607502000},"page":"1241-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Multiplex immunoassay measurement of amyloid-\u03b242 to amyloid-\u03b240 ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-8193","authenticated-orcid":false,"given":"Jonathan","family":"Vogelgsang","sequence":"first","affiliation":[]},{"given":"Hedieh","family":"Shahpasand-Kroner","sequence":"additional","affiliation":[]},{"given":"Rebekka","family":"Vogelgsang","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Streit","sequence":"additional","affiliation":[]},{"given":"Ruth","family":"Vukovich","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"5210_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC et al (2015) A practical guide to immunoassay method validation. Front Neurol 6:1\u20138. \n                    https:\/\/doi.org\/10.3389\/fneur.2015.00179","journal-title":"Front Neurol"},{"key":"5210_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.mcna.2013.01.001","volume":"97","author":"JL Cummings","year":"2013","unstructured":"Cummings JL, Dubois B, Molinuevo JL, Scheltens P (2013) International work group criteria for the diagnosis of Alzheimer disease. Med Clin N Am 97:363\u2013368. \n                    https:\/\/doi.org\/10.1016\/j.mcna.2013.01.001","journal-title":"Med Clin N Am"},{"key":"5210_CR3","unstructured":"Deuschl G, Maier W (2016) S3-Leitlinie \u201cDemenzen\u201d. \n                    http:\/\/www.dgn.org\/leitlinien\n                    \n                  . Accessed 29 November 2017. In: Deuschl G, Maier W S3-leitlin. Demenzen. Dtsch. Gesellschaft f\u00fcr Neurol. Hrsg. Leitlinien f\u00fcr Diagnostik und Ther. der Neurol. \n                    http:\/\/tinyurl.com\/hkwk6lf\n                    \n                  . Accessed 29 Nov 2017"},{"key":"5210_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734\u2013746. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(07)70178-3","journal-title":"Lancet Neurol"},{"key":"5210_CR5","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1681\/ASN.2014060607","volume":"26","author":"L Fan","year":"2015","unstructured":"Fan L, Levey AS, Gudnason V et al (2015) Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals. J Am Soc Nephrol 26:1982\u20131989. \n                    https:\/\/doi.org\/10.1681\/ASN.2014060607","journal-title":"J Am Soc Nephrol"},{"key":"5210_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, P\u00e9rez-Grijalba V, Pesini P et al (2017) Plasma A\u03b242\/40 ratios as biomarkers for A\u03b2 cerebral deposition in cognitively normal individuals. Alzheimer\u2019s Dement Diagn Assess Dis Monit 8:179\u2013187. \n                    https:\/\/doi.org\/10.1016\/j.dadm.2017.07.004","journal-title":"Alzheimer\u2019s Dement Diagn Assess Dis Monit"},{"key":"5210_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1021\/ac00265a021","volume":"56","author":"JV Gilfrich","year":"1984","unstructured":"Gilfrich JV, Birks LS (1984) Estimation of detection limits in X-ray fluorescence spectrometry. Anal Chem 56:77\u201379. \n                    https:\/\/doi.org\/10.1021\/ac00265a021","journal-title":"Anal Chem"},{"key":"5210_CR8","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1007\/s12035-015-9218-y","volume":"53","author":"J Gronewold","year":"2015","unstructured":"Gronewold J, Klafki H-W, Baldelli E et al (2015) Factors responsible for plasma \u03b2-amyloid accumulation in chronic kidney disease. Mol Neurobiol 53:3136\u20133145. \n                    https:\/\/doi.org\/10.1007\/s12035-015-9218-y","journal-title":"Mol Neurobiol"},{"key":"5210_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-2011-111418","volume":"28","author":"O Hansson","year":"2012","unstructured":"Hansson O, Stomrud E, Vanmechelen E et al (2012) Evaluation of plasma Abeta as predictor of Alzheimer\u2019s disease in older individuals without dementia: a population-based study. J Alzheimers Dis 28:231\u2013238. \n                    https:\/\/doi.org\/10.3233\/JAD-2011-111418","journal-title":"J Alzheimers Dis"},{"key":"5210_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/archneurol.2012.18107","volume":"69","author":"Y Huang","year":"2012","unstructured":"Huang Y, Potter R, Sigurdson W et al (2012) \u03b2-Amyloid dynamics in human plasma. Arch Neurol 69:1591\u20131597. \n                    https:\/\/doi.org\/10.1001\/archneurol.2012.1810","journal-title":"Arch Neurol"},{"key":"5210_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1602\/neurorx.1.2.226","volume":"1","author":"MC Irizarry","year":"2004","unstructured":"Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1:226\u2013234. \n                    https:\/\/doi.org\/10.1602\/neurorx.1.2.226","journal-title":"NeuroRx"},{"key":"5210_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert M, Knopman DS et al (2011) Introduction to revised criteria for the diagnosis of Alzheimer\u2019s disease: National Institute on Aging and the Alzheimer Association Workgroups. Alzheimer\u2019s Dement 7:257\u2013262. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2011.03.004","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"5210_CR13","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S et al (2016) Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 6:26801. \n                    https:\/\/doi.org\/10.1038\/srep26801","journal-title":"Nat Publ Gr"},{"key":"5210_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y et al (2014a) Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B 90:353\u2013364. \n                    https:\/\/doi.org\/10.2183\/pjab.90.353","journal-title":"Proc Jpn Acad Ser B"},{"key":"5210_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2183\/pjab.90.104","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Yamamoto R, Sato T-A, Tanaka K (2014b) Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. Proc Jpn Acad Ser B Phys Biol Sci 90:104\u2013117. \n                    https:\/\/doi.org\/10.2183\/pjab.90.104","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"5210_CR16","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/brain\/awl280","volume":"129","author":"H-W Klafki","year":"2006","unstructured":"Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J (2006) Therapeutic approaches to Alzheimer\u2019s disease. Brain 129:2840\u20132855. \n                    https:\/\/doi.org\/10.1093\/brain\/awl280","journal-title":"Brain"},{"key":"5210_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3233\/JAD-160398","volume":"54","author":"H-W Klafki","year":"2016","unstructured":"Klafki H-W, Hafermann H, Bauer C et al (2016) Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-\u03b2 peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimers Dis 54:691\u2013705. \n                    https:\/\/doi.org\/10.3233\/JAD-160398","journal-title":"J Alzheimers Dis"},{"key":"5210_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","volume":"25","author":"P Lewczuk","year":"2004","unstructured":"Lewczuk P, Esselmann H, Otto M et al (2004) Neurochemical diagnosis of Alzheimer\u2019s dementia by CSF A\u03b242, A\u03b242\/A\u03b240 ratio and total tau. Neurobiol Aging 25:273\u2013281. \n                    https:\/\/doi.org\/10.1016\/S0197-4580(03)00086-1","journal-title":"Neurobiol Aging"},{"key":"5210_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2016","unstructured":"Lewczuk P, Matzen A, Blennow K et al (2016) Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 55:813\u2013822. \n                    https:\/\/doi.org\/10.3233\/JAD-160722","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5210_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","volume":"13","author":"H L\u00f6vheim","year":"2017","unstructured":"L\u00f6vheim H, Elgh F, Johansson A et al (2017) Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 13:778\u2013782. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2016.12.004","journal-title":"Alzheimer\u2019s Dement"},{"key":"5210_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7:263\u2013269. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimer\u2019s Dement"},{"key":"5210_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttil\u00e4 T, Mehta SP et al (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1\u201340 and 1\u201342 in Alzheimer disease. Arch Neurol 57:100\u2013105. \n                    https:\/\/doi.org\/10.1001\/archneur.57.1.100","journal-title":"Arch Neurol"},{"key":"5210_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15:673\u2013684. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"key":"5210_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG et al (2017) Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer\u2019s Dement 13:841\u2013849. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","journal-title":"Alzheimer\u2019s Dement"},{"key":"5210_CR25","first-page":"112","volume":"18","author":"V Thomsen","year":"2003","unstructured":"Thomsen V, Schatzlein D, Mercuro D (2003) Limits of detection in spectroscopy. Pure Appl Chem 18:112\u2013114","journal-title":"Pure Appl Chem"},{"key":"5210_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","volume":"122","author":"JB Toledo","year":"2011","unstructured":"Toledo JB, Vanderstichele H, Figurski M et al (2011) Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122:401\u2013413. \n                    https:\/\/doi.org\/10.1007\/s00401-011-0861-8","journal-title":"Acta Neuropathol"}],"container-title":["Experimental Brain Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00221-018-5210-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-018-5210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-018-5210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T20:28:11Z","timestamp":1551126491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00221-018-5210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["5210"],"URL":"https:\/\/doi.org\/10.1007\/s00221-018-5210-x","relation":{},"ISSN":["0014-4819","1432-1106"],"issn-type":[{"value":"0014-4819","type":"print"},{"value":"1432-1106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"10 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}